Subchronic phencyclidine exposure potentiates the behavioral and c-Fos response to stressful stimuli in rats

Pharmacology Biochemistry and Behavior

Volumn 88, Issue 1, 2007, Pages 73-81

  Turgeon, Sarah M ^a   Lin, Tiffany ^a   Subramanian, Mrigaya ^a  

^a AMHERST COLLEGE   (United States)

Author keywords

Forced swim test; Novel environment; Nucleus accumbens; Prefrontal cortex; Schizophrenia; Striatum

Indexed keywords

PHENCYCLIDINE; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FORCED SWIMMING TEST; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LONG TERM EXPOSURE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SINGLE DRUG DOSE; STRESS;

ANIMALS; BEHAVIOR, ANIMAL; CEREBROVASCULAR CIRCULATION; EXCITATORY AMINO ACID AGONISTS; GENE EXPRESSION; GENES, FOS; HALLUCINOGENS; MALE; NEOSTRIATUM; NUCLEUS ACCUMBENS; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PSYCHOLOGICAL; SWIMMING;

RATTUS;

EID: 34548492003     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.07.005     Document Type: Article

References (43)

1. Abdel-Naby Sayed M., Noda Y., Hamdy M.M., Mamiya T., Nagai T., Furukawa H., et al. Enhancement of immobility induced by repeated phencyclidine injection: association with c-Fos protein in the mouse brain. Behav Brain Res 124 (2001) 71-76
2. Audet M.-C., Goulet S., and Dore F.Y. Repeated subchronic exposure to phencyclidine elicits excessive atypical grooming in rats. Behav Brain Res 167 (2006) 103-110
3. Badiani A., Oates M.M., Day H.E.W., Watson S.J., Akil H., and Robinson T.E. Amphetamine-induced behavior, dopamine release, and c-Fos expression: modulation by environmental novelty. J Neurosci 12 (1998) 10579-10593
4. Badiani A., Oates M.M., Fraioli S., Browman K.E., Ostrander M.M., Wolf M.E., et al. Environmental modulation of the response to amphetamine: dissociation between changes in behavior and changes in dopamine and glutamate overflow in the rat striatal complex. Psychopharmacology 151 (2000) 166-174
5. Bardo M.T., Bowling S.L., and Peirce R.C. Changes in locomotion and dopamine neurotransmission following amphetamine, haloperidol, and exposure to novel environmental stimuli. Psychopharmacology 101 (1990) 338-343
6. Barrot M., Marinelli M., Abrous D.N., Rouge-Pont F., Le Moal M., and Piazza P.V. Functional heterogeneity in dopamine release and in the expression of Fos-like proteins within the rat striatal complex. Eur J Neurosci 11 (1999) 1155-1166
7. Butterweck V., Prinz S., and Schwaninger M. The role of interleukin-6 in stress-induced hyperthermia and emotional behavior in mice. Behav Brain Res 144 (2003) 49-56
8. Connor T.J., Kelliher P., Harkin A., Kelly J.P., and Leonard B.E. Reboxetine attenuates forced swim test-indued behavioral and neurochemical alterations in the rat. Eur J Pharmacol 379 (1999) 125-133
9. Cullinan W.E., Herman J.P., Battaglia D.F., Akil H., and Watson S.J. Pattern and time course of immediate early gene expression in rat brain following acute stress. Neuroscience 64 (1995) 477-505
10. Deutch A.Y., Clark W.A., and Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res 521 (1990) 311-315
11. Duncan G.E., Johnson K.B., and Breese G.R. Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J Neurosci 13 (1993) 3932-3943
12. Duncan G.E., Knapp D.J., Johnson K.B., and Breese G.R. Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. J Pharmacol Exp Ther 277 (1996) 1076-1089
13. Ellenbroek B.A., and Cools A.R. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11 (2000) 223-233
14. Emmert M.H., and Herman J.P. Differential forebrain c-fos mRNA induction by ether inhalation and novelty: evidence for distinctive stress pathways. Brain Res 845 (1999) 60-67
15. Ferguson S.M., Norton C.S., Satson S.J., Akil H., and Robinson T.E. Amphetamine-evoked c-fos mRNA expression in the caudate-putamen: the effects of DA and NMDA receptor antagonists vary as a function of neuronal phenotype and environmental context. J Neurochem 86 (2003) 33-44
16. File S.E., and Tucker J.C. Behavioral consequences of antidepressant treatment in rodents. Neurosci Biobehav Rev 10 (1986) 123-134
17. Hanania T., Hillman G.R., and Johnson K.M. Augmentation of locomotor activity by chronic phencyclidine is associated with an increase in striatal NMDA receptor function and an upregulation of the NR1 receptor subunit. Synapse 31 (1999) 229-239
18. Handa R.J., Nunley K.M., and Bollnow M.R. Induction of c-fos mRNA in the brain and anterior pituitary gland by a novel environment. NeuroReport 4 (1993) 1079-1082
19. Ho Y.-J., Chang Y.-C., Liu T.-M., Tai M.-Y., Wong C.-S., and Tsai Y.-F. Striatal glutamate release during novelty exposure-induced hyperactivity in olfactory bulbectomized rats. Neurosci Lett 287 (2000) 117-120
20. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiat 148 (1991) 1301-1308
21. Jentsch J., Taylor J., and Roth R. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress-and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19 (1998) 105-113
22. Jentsch J.D., Tran A., Dung Le B.A., Youngren K.D., Phil M., and Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17 (1997) 92-99
23. Kirby L.G., and Lucki I. Interaction between the forced swimming test and fluoxetine treatment on extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the rat. J Pharmacol Exp Ther 282 (1997) 967-976
24. Kirby L.G., Chou-Green J.M., Davis K., and Lucki I. The effects of different stressors on extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid. Brain Res 760 (1997) 218-230
25. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., and Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 30 (2005) 1883-1894
26. Liebsch G., Montkowski A., Holsboer F., and Landgraf R. Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour. Behav Brain Res 94 (1998) 301-310
27. Markou A., and Kenny P.J. Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories. Neurotox Res 4 (2002) 297-313
28. Noda Y., Yamada K., Furukawa H., and Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 116 (1995) 2531-2537
29. Noda Y., Takayoshi M., Furukawa H., and Nabeshima T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Euro J Pharmcol 324 (1997) 135-140
30. Noda Y., Kamei H., Mamiya M.S., Furukawa H., and Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharm 23 (2000) 375-387
31. Okuyama S., Ogawa S.-I., Nakazato A., and Tomizawa K. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci Lett 189 (1995) 60-62
32. Paxinos G., and Watson C. The Brain in Stereotaxic Coordinates. 2nd Ed (1986), Academic Press, Sydney
33. Piazza P.V., Rouge-Pont F., Deminiere J.M., Kharoubi M., Le Moal M., and Simon H. Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration. Brain Res. 567 (1991) 169-174
34. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19 (1998) 18-25
35. Schwabe K., Klein S., and Koch M. Behavioural effects of neonatal lesions of the medial prefrontal cortex and subchronic pubertal treatment with phencyclidine of adult rats. Behav Brain Res 168 (2006) 150-160
36. Spieleway C., and Markou A. Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology 28 (2003) 1106-1116
37. Strekalova T., Spanagel R., Bartsch D., Henn F., and Gass P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology 29 (2004) 2007-2017
38. Trullas R., and Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185 (1990) 1-10
39. Turgeon S.M., and Roche J.K. The delayed effects of phencyclidine enhance amphetamine-induced behavior and striatal c-Fos expression in the rat. Neuroscience 91 (1999) 1265-1275
40. Turgeon S.M., and Reichstein D.A. Decreased striatal c-Fos accompanies latent inhibition in a conditioned taste aversion paradigm. Brain Res 924 (2002) 120-123
41. Turgeon S.M., and Hoge S.G. Prior exposure to phencyclidine decreases voluntary sucrose consumption and operant performance for food reward. Pharmacol Biochem Behav 76 (2003) 393-400
42. Turgeon S.M., Auerbach E.A., and Heller M.A. The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm. Pharmacol Biochem Behav 60 (1998) 553-558
43. Yeap S., and Thakore J.H. Stress axis dysfunction in schizophrenia. Eur Psychiatr 20 (2005) 8307-8312